Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 3/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL20531399 | 1.00 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4901 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1972366 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 0.99 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 0.98 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652202 | 0.98 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395674 | 0.98 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071438-B | Process for preparing fexofenadine and intermediates used therein | 赛诺菲-安万特德国有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3365327-B1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-11-20 | — | — | EP | disclosed |
| CN-109071438-A | Process for the preparation of fexofenadine and intermediates used therein | 赛诺菲-安万特德国有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3365327-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | Sanofi-Aventis Deutschland GmbH (DE) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068129-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-04-27 | — | — | WO | disclosed |
| US-9504656-B2 | Pharmaceutical compositions for poorly soluble active ingredients | Banner Life Sciences, LLC (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150108033-A1 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE ACTIVE INGREDIENTS | PATHEON SOFTGELS INC | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | CYP4F2, CYP4F3, NISCH | HRH1 39/4885KCNH2 458/4885LMNA 3359/4885 |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | CYP4F2, CYP4F3, NISCH | HRH1 39/4885KCNH2 458/4885LMNA 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.